Ocugen, Inc.
OCU410
geographic atrophy secondary to dry age-related macular degeneration
Resolved
173days ago
Phase 1 readout · Jan 15, 2026
What's at stake
Phase 1 trial results for OCU410 in geographic atrophy secondary to dry age-related macular degeneration are due Jan 15, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Phase 1 (~50% of patients evaluated to date at 12 months) shows 60% slower EZ loss in OCU410-treated eyes compared to untreated fellow eyes at 12 months”